Multicomponent therapeutics for networked systems
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Therapeutic regimens that comprise more than one active ingredient are commonly used in clinical medicine. Despite this, most drug discovery efforts search for drugs that are composed of a single chemical entity. A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. A systems perspective facilitates an understanding of the mechanism of action of such drug combinations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1705]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“There have been attempts to systematize a set of principles that can account for combination drugs that exist toda”
BackgroundLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · cited 1×
“Numerous researchers have attempted to provide an unambiguous framework for the calculation of additive effects between compounds; these approaches are reviewed comprehensively elsewher”
BackgroundSystematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundDolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Self-citation
Research works printed but not linked: 2
- Ehrlich, P. Chemotherapeutics: scientific principles, methods and results. Lancet 2, 445–451 (1913).
- Albert, A. Selective Toxicity (Methuen & Co., London, 1968).
Cited by
Items 401–500 of 799
Moinuddin, S. M., Shi, Q., Tao, J., Guo, M., Zhang, J., Xue, Q., Ruan, S., & Cai, T. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-019-1578-6 · Cited by 22
Li, P., Shi, X., Wei, Y., Qin, L., Sun, W. C., Xu, G., Xu, T., & Liu, T. (2015) · Molecules · doi:10.3390/molecules200917016 · Cited by 22
“In the other words, the goal is to identify highly selective drugs that act on a single target [4].”
BackgroundAn Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases
Li, P., Nie, Y., & Yu, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143045 · Cited by 26
“However, the traditional strategy of “one disease-one target-one drug” is no longer effective and challenged in many cases, especially with regard to multi-factorial diseases [3, 4], which is the case for neurodegenerative disorders.”
BackgroundA network perspective on unraveling the role of TRP channels in biology and disease
Chun, J. N., Lim, J. M., Kang, Y. A., Kim, E. H., Shin, Y.-C., Kim, H., Jang, D., Kwon, D., Shin, S.-Y., So, I., et al. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1292-2 · Cited by 21
“Network-based approaches are also considered innovative for the development of drug discovery and repositioning strategies, including polypharmacology (or multicomponent therapeutics) and network pharmacology [4, 12, 38, 40, 54, 76].”
BackgroundBarbari, R., Tupini, C., Durini, E., Gallerani, E., Nicoli, F., Lampronti, I., Baldisserotto, A., & Manfredini, S. (2022) · Molecules · doi:10.3390/molecules28010287 · Cited by 23
Tang, W., Zhang, Y., Li, P., & Li, B. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03767 · Cited by 21
Yadav, P., & Malpathak, N. (2016) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.50.3.25 · Cited by 24
Wu, C., Lu, Z., Rong, Y., Zhu, G., Liang, S., & Wang, S. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.09.011 · Cited by 21
Qu, Y., Zhang, Z., Lu, Y., Zheng, D., & Yang, W. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/3865121 · Cited by 21
O’Hagan, S., Knowles, J. D., & Kell, D. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048862 · Cited by 22
“[94–108]).”
Wáng, Y., Yu, L., Zhang, L., Qu, H., & Cheng, Y. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00934.x · Cited by 20
“The multivariate regression function for infarct rate of heart was shown in eqn (5), and the function for MDA was shown in eqn (6).”
BackgroundKanegan, M. J. V., Dunn, D., Kaltenbach, L. S., Shah, B. D., Dong, H., McCoy, D. D., Yang, P., Peng, J., Shen, L., Du, L., et al. (2016) · Scientific Reports · doi:10.1038/srep25626 · Cited by 21
Zhu, Z., Song, Z., Cao, L., Wang, Y., Zhou, W., Zhou, P., & Zuo, F. (2018) · Animal Science Journal · doi:10.1111/asj.12978 · Cited by 20
Li, C., Dai, L., Liu, K., Deng, L., Pei, T., & Lei, J. (2015) · RSC Advances · doi:10.1039/c5ra15375a · Cited by 20
Song, H. L., Zhou, S., Wang, R., & Li, S. (2013) · ChemMedChem · doi:10.1002/cmdc.201300228 · Cited by 23
Zhang, B., Zhao, Y. F., Zhai, X., Fan, W. J., Ren, J. L., Wu, C. F., & Gong, P. (2012) · Chinese Chemical Letters · doi:10.1016/j.cclet.2012.06.009 · Cited by 20
Vardanyan, R., Vijay, G., Nichol, G. S., Liu, L., Kumarasinghe, I. R., Davis, P., Vanderah, T. W., Porreca, F., Lai, J. Y., & Hruby, V. J. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.065 · Cited by 21
Trustworthy Deep Neural Network for Inferring Anticancer Synergistic Combinations
Alsherbiny, M. A., Radwan, I., Moustafa, N., Bhuyan, D. J., El-Waisi, M., Chang, D., & Li, C. G. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3126339 · Cited by 19
da Costa, J. M., Brito, S., Campos, A., & Rodrigues, F. (2012) · Pharmacognosy Magazine · doi:10.4103/0973-1296.96550 · Cited by 19
“The increasing incidence of adverse side effects associated with conventional drugs, and the emergence of resistance to antibiotics[1,2] justifies the search for new drugs from vegetable species in order to combat the multiresistant microorganisms.”
BackgroundSystems biology: A biologist's viewpoint
Bose, B. (2013) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2013.07.001 · Cited by 20
“Several authors have used this concept to propose development of multicomponent therapeutics and multi-target drugs (Keith et al., 2005; Csermely et al., 2005).”
BackgroundKashif, M., Andersson, C. R., Åberg, M., Nygren, P., Sjöblom, T., Hammerling, U., Larsson, R. L., & Gustafsson, M. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0430 · Cited by 20
“been explicitly ignored, for example, in the already mentioned review by Greco and colleagues (7), its importance has been acknowledged many times in the past (2, 4, 14, 15).”
BackgroundSimulating Serial-Target Antibacterial Drug Synergies Using Flux Balance Analysis
Krueger, A., Munck, C., Dantas, G. A., Church, G. M., Galagan, J. E., Lehár, J., & Sommer, M. O. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147651 · Cited by 19
“Drug combinations can 55 overcome resistance by creating new therapeutic avenues inaccessible to single target 56 drugs [1-3] or eliminating functional redundancies exhibited by robust biological networks [4].”
BackgroundBrullo, C., Massa, M., Rapetti, F., Alfei, S., Bertolotto, M. B., Montecucco, F., Signorello, M. G., & Bruno, O. (2020) · Molecules · doi:10.3390/molecules25040899 · Cited by 19
Zhao, W., Song, L.-J., & Deng, H. (2011) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0813-0 · Cited by 19
Selective antagonism of anticancer drugs for side-effect removal
Fernández, A., & Sessel, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.001 · Cited by 20
QSAR Applications During Last Decade on Inhibitors of Acetylcholinesterase in Alzheimer’s Disease
Wong, K., Duchowicz, P. R., Mercader, A. G., & Castro, E. A. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712802762365 · Cited by 19
Rickles, R. J., Tam, W. F., Giordano, T. P., Pierce, L. T., Farwell, M., McMillin, D. W., Necheva, A. S., CROWE, D. F., Chen, M., Avery, W., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0925 · Cited by 21
“1S cells in 384-well plates at 1,000 to 1,500 cells per well, cultured for 18 to 24 hours, and treatedwith increasing concentrations of each drug to generate a dose matrix (4, 5).”
MethodSelf-citationMillan, M. J., Dekeyne, A., Gobert, A., la Cour, C. M., Brocco, M., Rivet, J., Cara, B. D., Lejeune, F., Cremers, T. I. F. H., Flik, G., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.04.003 · Cited by 19
“One strategy for attaining this goal is the co-administration of NK1 antagonists and SSRIs, but the development of drug combinations is challenging (Keith et al., 2005; Millan, 2006).”
BackgroundEnhanced bioavailability and safety of curcumagalactomannosides as a dietary ingredient
Liju, V. B., Jeena, K., Kumar, D., Maliakel, B. P., Kuttan, R., & Krishnakumar, I. M. (2014) · Food & Function · doi:10.1039/c4fo00749b · Cited by 19
Hemoglobin and hematocrit: an analysis of clinical accuracy. Case study of the anemic patient.
Keen, M. L. (1998) · PubMed · Cited by 23
Non-monotonic dynamics and crosstalk in signaling pathways and their implications for pharmacology
van Wijk, R., Tans, S. J., ten Wolde, P. R., & Mashaghi, A. (2015) · Scientific Reports · doi:10.1038/srep11376 · Cited by 19
Ojha, D., Mukherjee, H., Ghosh, S., Bag, P., Mondal, S., Chandra, N. S., Mondal, K. C., Samanta, A., Chakrabarti, S., & Chattopadhyay, D. (2013) · Journal of Applied Microbiology · doi:10.1111/jam.12330 · Cited by 19
Proof concept for clinical justification of network mapping for personalized cancer therapeutics
Nemunaitis, J. J., Senzer, N. N., Khalil, I. G., Shen, Y., Kumar, P., Tong, A., Kuhn, J. A., Lamont, J. P., Nemunaitis, M., Rao, D., et al. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701057 · Cited by 20
Ogaki, R., Gilmore, I. S., Alexander, M. R., Green, F. M., Davies, M. C., & Lee, J. L. S. (2011) · Analytical Chemistry · doi:10.1021/ac200347a · Cited by 19
Antimicrobial agents from natural sources: An overview
Paul, R. K., Dutta, D., Chakraborty, D., Nayak, A., Dutta, P. K., & Nag, M. (2019) · Advance Pharmaceutical Journal · doi:10.31024/apj.2019.4.2.1 · Cited by 18
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Jassem, S., Wang, W., Sweet, H., Manoukian, R., Chow, V., Kanakaraj, P., Hutterer, K. M., Kuhns, S. T., Foltz, I. N., Chen, Q., et al. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2702-8 · Cited by 19
Jank, B. J., Lenz, T., Haas, M., Kadletz‐Wanke, L., Campion, N. J., Schnoell, J., Heiduschka, G., & Macfelda, K. (2022) · Investigational New Drugs · doi:10.1007/s10637-021-01207-1 · Cited by 18
“In brief, the combined effect (ET) expressed as the surviving fraction is modelled as the product of the individual effects with drug “A” (EA) and “B” (EB), computed by: ET = EA x EB [14].”
MethodIrfan, I., Ali, A., Reddi, B., Khan, M. A., Hasan, P., Ahmed, S., Uddin, A., Piatek, M. E., Kavanagh, K. A., Haque, Q. M. R., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11081126 · Cited by 18
Shi, Z., Ma, X. H., Qin, C., Jia, J., Jiang, Y., Tan, C., & Chen, Y. (2011) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2011.09.002 · Cited by 18
Platelet Aggregation Pathway Network-Based Approach for Evaluating Compounds Efficacy
Gu, J., Li, Q., Chen, L., Li, Y., Hou, T., Yuan, G., & Xu, X. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/425707 · Cited by 18
“Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 425707, 8 pages http://dx.doi.org/10.1155/2013/425707”
BackgroundInfluentialChem2Bio2RDF: A Linked Open Data Portal for Systems Chemical Biology
Chen, B., Ding, Y., Wang, H., Wild, D. J., Dong, X., Sun, Y., Zhu, Q., & Sankaranarayanan, M. (2010) · IEEE/WIC/ACM International Conference on Web Intelligence and Intelligent Agent Technology (WI-IAT) · doi:10.1109/wi-iat.2010.183 · Cited by 18
Sidhu, H., Gautam, L. K., & Capalash, N. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10429-1 · Cited by 17
“Therapeutic opportunities are often lost while discovering drugs that target single genes [52].”
BackgroundLiu, J., Shi, J., Guo, J., Chen, Y., Ma, X.-J., Wang, S., Zheng, Z.-Q., Lin, M.-X., & He, S. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03829-1 · Cited by 20
“side effects and resistances in clinic [55, 56].”
Towards the routine use of in silico screenings for drug discovery using metabolic modelling
Bintener, T., Pacheco, M. P., & Sauter, T. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190867 · Cited by 18
Oruganti, L., & Meriga, B. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200807115647 · Cited by 20
Synthesis and leishmanicidal activity of quinoline–triclosan and quinoline–eugenol hybrids
Arango, V., Domínguez, J. J., Cardona, W., Robledo, S. M., Muñoz, D. L., Figadère, B., & Sáez, J. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9886-8 · Cited by 17
“The combination of two pharmacological agents into a single molecule, called hybrid molecules, is an emerging strategy in medicinal chemistry and drug discovery research (Keith et al., 2005; Roth et al., 2004).”
Making Sense of Antisense in Antibiotic Drug Discovery
Wright, G. D. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.08.009 · Cited by 17
Wahid, M., Mandal, R. K., Dar, S. A., Jawed, A., Lohani, M., Areeshi, M. Y., Akhter, N., & Haque, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.009 · Cited by 17
Chemical Genetics and Orphan Genetic Diseases
Lunn, M. R., & Stockwell, B. R. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.005 · Cited by 19
“Correspondingly, this combination therapy approach has already proven to be valuable in high-throughput screens [118, 119].”
BackgroundSelf-citationChen, J., Mao, Y., Xing, C., Hu, R., Xu, Z., Cao, H., & Luo, J. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/3647525 · Cited by 16
“Due to the complicated pathogenesis and progression of diarrhea, the therapeutic effect of a single herb may be modest in the clinic [9].”
BackgroundMDNNSyn: A Multi-Modal Deep Learning Framework for Drug Synergy Prediction
Li, L., Li, H., Ishdorj, T.-O., Zheng, C.-H., & Su, Y. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3421916 · Cited by 16
“For example, chlorpromazine and pentamidine, when used in isolation, are no indication of tumor suppressive activity, but the combination of them creates synergistic effect on inhibiting tumor growth [5].”
BackgroundSynergistic Synthetic Biology: Units in Concert
Trosset, J., & Carbonell, P. (2013) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2013.00011 · Cited by 16
“…and other side effects associated with high doses of single drugs by countering biological compensation, allowing reduced dosage of each compound, or accessing context-specific multi-target mechanisms (Roth et al., 2004; Sharom et al., 2004; Kaelin, 2005; Keith et al., 2005; Hopkins, 2008).”
Tibetische Arzneimittel in Europa: Historische, praktische und regulatorische Aspekte
Schwabl, H., Geistlich, S., & McHugh, E. (2006) · Forschende Komplementärmedizin / Research in Complementary Medicine · doi:10.1159/000090732 · Cited by 16
Research on Human Body Movement Posture Based on Inertial Sensor
Zhang, L. (2018) · International Journal Bioautomation · doi:10.7546/ijba.2018.22.2.179-186 · Cited by 16
Kumar, V., Kumar, A., Joseph, V., Dan, V. M., Jaleel, A., Kumar, T. R. S., & Kartha, C. S. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03637-1 · Cited by 19
Repash, E. M., Pensabene, K. M., Palenchar, P. M., & Eggler, A. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.686201 · Cited by 16
“The usefulness of response surfaces in interaction analyses is becoming appreciated, as the benefit of a combination therapy is often dependent on the doses administered (Prichard and Shipman, 1990; Keith et al., 2005; Foucquier and Guedj, 2015).”
BackgroundRitacca, A. G., Ritacco, I., Dabbish, E., Russo, N., Mazzone, G., & Sicilia, E. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00262 · Cited by 17
Han, T., Liu, Y., Chen, Y., Chen, T., Li, Y., Li, Q., & Zhao, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2663758 · Cited by 18
“Advances in systems biology are revealing a phenotypic robustness and network structure that strongly suggests that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical e ffi cacy [10 – 12].”
Xie, Q., Gao, S., Tian, R., Wang, G., Qin, Z., Chen, M., Zhang, W., Wen, Q., Ma, Q., & Zhu, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s393862 · Cited by 16
Sales, D. L., Oliveira, O. P., Cabral, M. E. S., Dias, D. D. Q., Kerntopf, M. R., Coutinho, H. D. M., da Costa, J. G. M., de Freitas, F. R. D., Ferreira, F. S., Alves, R. R. N., et al. (2014) · Pharmaceutical Biology · doi:10.3109/13880209.2014.911331 · Cited by 17
“, 2007; Varaldo, 2002), a number of authors have reported the use of multi-drug treatments (Keith et al., 2005) composed of combinations Correspondence: Researcher Débora Lima Sales, Programa de Pós-Graduação em Etnobiologia e Conservação da Natureza, Universidade Federal Rural de Pernambuco – UFRPE, Rua Dom Manoel de…”
BackgroundScreening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
Kim, I., Kim, J. H., & Oh, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00661 · Cited by 16
Zhou, W., Tan, X., Shan, J., Wang, S., Yin, A., Cai, B., & Di, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109619 · Cited by 15
Computational Predictions for Multi-Target Drug Design
Gupta, N., Pandya, P., & Verma, S. (2018) · Methods in pharmacology and toxicology · doi:10.1007/7653_2018_26 · Cited by 18
Liu, L., Liu, Q., Li, P., & Liu, E. (2018) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(18)30108-0 · Cited by 15
Combined antitumoral effects of pretubulysin and methotrexate
Kern, S., Truebenbach, I., Höhn, M., Gorges, J., Kazmaier, U., Zahler, S., Vollmar, A. M., & Wagner, E. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.460 · Cited by 15
Huang, C., Xu, T., Li, Y., & Ren, J. (2022) · Food Frontiers · doi:10.1002/fft2.162 · Cited by 16
Discovering molecular targets in cancer with multiscale modeling
Wang, Z., Bordas, V., & Deisboeck, T. S. (2010) · Drug Development Research · doi:10.1002/ddr.20401 · Cited by 17
“The combination of targeted drugs is considered a promising strategy to improve treatment efficacy, reduce off-target effects, and/or prevent evolution of drug resistance [Borisy et al., 2003; Chou, 2006; Keith et al., 2005].”
BackgroundBansal, Y., & Silakari, O. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0282-4 · Cited by 15
Drug Discovery: From Hits to Clinical Candidates
Célanire, S., Lebon, F., & Stark, H. (2008) · CRC Press eBooks · doi:10.1201/9781420053937-5 · Cited by 15
Morphy, R., & Ranković, Z. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00019-5 · Cited by 15
Varma, H., Gangadhar, N. M., Letso, R. R., Wolpaw, A. J., Sriramaratnam, R., & Stockwell, B. R. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.019 · Cited by 14
“…States bDepartment of Chemistry, Columbia University, Northwest Corner Building, MC 4846, 550 West 120th Street, New York, NY 10027, United States cDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, United States a r t i c l e i n f o r m a t i o n”
BackgroundSelf-citationBiological Networks and Drug Discovery—Where Do We Stand?
Geppert, T., & Koeppen, H. (2014) · Drug Development Research · doi:10.1002/ddr.21207 · Cited by 16
“Isolated fractions of natural extracts often do not show activity which may reflect the need for synergistic interactions in the components present in the original extract [Yuan and Lin, 2000; Keith et al., 2005].”
BackgroundMathew, D., Lidiya John, P., Manila, T. M., Divyasree, P., & Sandhya Rajan, V. T. K. (2017) · Food Science and Human Wellness · doi:10.1016/j.fshw.2017.09.003 · Cited by 14
“Emergence of resistance to antibiotics and adverse side effects associated with conventional drugs demands the search for new plant based drugs [54,55].”
BackgroundLiu, H., Tang, S.-Z., Lü, S., Ran, T., Wang, J., Zhang, Y., Xu, A., Lu, T., & Chen, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024451 · Cited by 14
“One of the multi-target strategies involves developing a single drug that can simultaneously act on two or multiple targets, which is more predictable on the pharmacokinetics and pharmacodynamics [7–12].”
BackgroundChemical-Chemical Combinations Map Uncharted Interactions in Escherichia coli under Nutrient Stress
Zahed, S. S. E., & Brown, E. D. (2018) · iScience · doi:10.1016/j.isci.2018.03.018 · Cited by 14
“Binary combination space for n compounds is defined by the formula n*(n-1)/2 (Keith et al., 2005).”
BackgroundAlexis, F. (2014) · Molecular Therapy · doi:10.1038/mt.2014.96 · Cited by 14
Tseng, Y., Yang, T.-J., Hsu, Y., Liu, J., Tseng, Y., Hsu, T.-W., Lu, Y., Pan, S., Cheng, T.-J. R., & Fang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116042 · Cited by 13
Shakir, M., Ali, A., Lakshmi, S., Garg, M., Almuqdadi, H. T. A., Irfan, I., Kamthan, M., Joshi, M. C., Javed, S., Rawat, D. S., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117127 · Cited by 13
Wang, L., Yang, X., Song, Q., Fu, J., Wang, W., Du, K., Chen, S., Cao, J., Huang, R., & Zou, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.617555 · Cited by 13
“Previous research for new drugs that target single gene or protein may overlook important therapeutic opportunities (Keith et al., 2005).”
BackgroundWang, T.-T., Hong, Y., Chen, Z., Wu, D., Yang, L., Wu, X., Huang, H., Zhang, Q., & Jia, C. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.04.047 · Cited by 13
Zaharieva, M. M., Trochopoulos, A., Dimitrova, L. L., Berger, M. R., Najdenski, H. M., Konstantinov, S., & Kroumov, A. D. (2018) · International Journal Bioautomation · doi:10.7546/ijba.2018.22.2.87-106 · Cited by 13
“If we use the neologism “-omics” (which refers to fields of study in biology known as genomics, proteomics or metabolomics), we should highlight that the recent advances in Omics and cell biology have a great impact on the increasing use of drug combinations in the modern medicine [16].”
MethodDakik, P., McAuley, M., Chancharoen, M., Mitrofanova, D., Rodriguez, M. E. L., Junio, J. A. B., Lutchman, V., Cortes, B., Simard, É., & Titorenko, V. I. (2019) · Oncotarget · doi:10.18632/oncotarget.26553 · Cited by 15
Small Molecule Effectors of Myosin Function
Manstein, D. J., & Preller, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38062-5_5 · Cited by 13
Paudel, P., Shrestha, S., Park, S. E., Seong, S. H., Fauzi, F. M., Jung, H. A., & Choi, J. S. (2020) · ACS Omega · doi:10.1021/acsomega.0c03649 · Cited by 14
Systems Biology and Cancer Prevention: All Options on the Table
Rosenfeld, S., & Kapetanović, I. M. (2008) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s1114 · Cited by 13
“Another example of oncogenic pathway redundancy and crosstalk involves TGF-β [3].”
BackgroundDual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263
Tosun, N. G., & Kaplan, Ö. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07587-1 · Cited by 12
Hu, Y., Zhou, Y., Shan, L., Shen, Y., Liu, L., & Chen, J. (2023) · Aquaculture · doi:10.1016/j.aquaculture.2023.740246 · Cited by 12
Systems biology visualization tools for drug target discovery
Huan, T., Wu, X., & Chen, J. Y. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003725102 · Cited by 12
“…and disease-modifying genes that span multiple pathways [80] Evaluate new multi-component drugs on metabolic changes as new therapeutic solutions [31] Molecule docking and drug screening AutoDock [81] , GOLD [82] , FlexX [83] , DOCK [84] , ICM [33] , PostDock [85] Dock drug to protein structures…”
BackgroundPlant-Derived Natural Products for the Treatment of Leishmaniasis
(2013) · Studies in natural products chemistry · doi:10.1016/b978-0-444-62615-8.00011-4 · Cited by 12
Morphy, R., & Ranković, Z. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00027-5 · Cited by 12
Liu, J., Gefen, O., Zhang, Z., Liu, M., Bar‐Meir, M., & Balaban, N. Q. (2022) · mBio · doi:10.1128/mbio.00004-22 · Cited by 13
Injectable, Anti-Cancer Drug-Eluted Chitosan Microspheres against Osteosarcoma
Zhao, J., Tian, H., Shang, F., Lv, T., Chen, D., & Feng, J. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13030091 · Cited by 12
Epigenetic engineering to reverse the Parkinson’s expression state
Valente, A. X. C. N., das Neves, R. P., & Oliveira, P. J. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.04.018 · Cited by 12
Vergara, S., Cardá, M., Agut, R., Yepes, L. M., Vélez, I. D., Robledo, S. M., & Galeano, W. C. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-2019-2 · Cited by 12
“In recent years a promising strategy has emerged based on hybrid molecules, which bear in their structures two distinct pharmacophores having, for example, anti-protozoal, antiinflammatory, anti-fungal, or anti-cancer activity, thus showing a dual mode of action (Keith et al. 2005; Meunier 2008).”
BackgroundDiker, N. Y., & Kutluay, V. M. (2021) · Food Bioscience · doi:10.1016/j.fbio.2021.100920 · Cited by 12
Vashist, U., Carvalhaes, R., D’Agosto, M., & da Silva, A. D. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00877.x · Cited by 12
“The combination of two separate pharmacological agents into a single molecule is an emerging strategy within medicinal chemistry and drug discovery (23).”
BackgroundEditorial: Computational and Experimental Approaches in Multi-target Pharmacology
Anastasio, T. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00443 · Cited by 12
“Several recent surveys describe the current landscape (Keith et al., 2005; Boran and Iyengar, 2010; Xie et al., 2012; Reddy and Zhang, 2013; Billur Engin et al., 2014; Bulusu et al., 2016).”
BackgroundLin, A., Che, C., Jiang, A., Qi, C., Glaviano, A., Zhao, Z., Zhang, Z., Liu, Z., Zhou, Z., Cheng, Q., et al. (2025) · Advanced Science · doi:10.1002/advs.202507764 · Cited by 13
Computational pharmacological studies on cardiovascular disease by Qishen Yiqi Diwan
Gu, J., Yuan, G., Zhu, Y., & Xu, X. (2009) · Science China Chemistry · doi:10.1007/s11426-009-0274-x · Cited by 12
Targeting melanoma by small molecules: challenges ahead
Haq, R., & Fisher, D. E. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12109 · Cited by 12
“Network analysis suggests that overcoming network robustness may require targeting several molecular vulnerabilities simultaneously, which significantly challenges current generation screening methods (Keith et al., 2005).”
Background
Metadata
- Authors
- Keith, C. T., Borisy, A. A., & Stockwell, B. R.
- Affiliations
- Columbia University (US)
- Corresponding author
- Keith, Curtis T.
- Borisy, Alexis A.
- Stockwell, Brent R.
- ORCID
- Stockwell, Brent R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-01
- Volume
- 4
- Issue
- 1
- Pages
- 71-78
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1592483428
- Cited by
- 769
- References
- 67
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 30 · 2023: 33 · 2022: 44 · 2021: 36 · 2020: 34 · 2019: 36 · 2018: 42 · 2017: 29 · 2016: 43 · 2015: 51 · 2014: 55 · 2013: 49 · 2012: 47
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- combination therapy, systems biology, mechanism of action, drug discovery
- MeSH terms
- Clinical Trials as Topic, Drug Synergism, Drug Therapy, Combination, Humans, Terminology as Topic, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.